Analyses Suggest No Causal Effect of Smoking Behavior on Chronic Kidney Disease
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 9, 2025 -- Smoking behavior seems to not have a causal effect on chronic kidney disease (CKD) risk in White individuals, according to a study published online Nov. 4 in Health Data Science.
In a traditional observational study, Zhilong Zhang, from the Peking University Health Science Center in Beijing, and colleagues used data from the U.K. Biobank cohort for adults aged 40 to 69 years to examine the associations between smoking indices, including smoking status and lifetime smoking index, and incident CKD stages 3 to 5. A potential causal effect was then estimated using Mendelian randomization (MR) approaches. The causal associations with CKD stages 3 to 5 were examined in one-sample MR using genetic variants associated with lifetime smoking index among 344,255 U.K. Biobank participants with White British ancestry. The findings were validated by a two-sample MR analysis using information from the Chronic Kidney Disease Genetics Consortium genome-wide association study.
The researchers found that both smoking status and lifetime smoking index were associated with a higher risk for incident CKD in the traditional observational study (hazard ratios, 1.26 and 1.22, respectively). However, in one- and two-sample MR analyses, no causal association was seen between lifetime smoking index and CKD. The genetic instruments were validated by statistical tests; similar results to the main model were seen in all sensitivity analyses.
"Given the substantial evidence linking smoking to CKD, further mediation analysis is needed to understand the intricate mechanisms between smoking behavior and CKD," the authors write. "Such an analysis is essential for generating valuable insights that can inform and enhance public health strategies focused on mitigating CKD risk factors and improving overall kidney health."
One author reported being deputy editor of Health Data Science.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-01-11 00:00
Read more
- FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara
- FDA Approves Tryngolza (olezarsen) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome
- The Number of Homeless People in the U.S. Has Increased
- FDA Approves Vtama (tapinarof) Cream for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
- Study Compares Single-Inhaler Triple Therapies for Treatment of COPD
- Adoption of Acute Hospital Care at Home Program Limited to Specific Types of Hospitals
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions